文献速递冠心病

左主干病变药物洗层支架PCI与CABG十年随访结果(PRECOMBAT试验延长随访)

Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.
PubMed 文献 · Circulation · 2020-03-30

10年时主要心脑血管不良事件发生率PCI组29.8%、CABG组24.7%(HR 1.25,95%CI 0.93-1.69),死亡、心肌梗死或卒中复合终点及全因死亡率均无显著差异,但PCI组缺血驱动靶血管血运重建更频繁。

要点

  • 10年主要心脑血管不良事件PCI与CABG无显著差异(29.8% vs 24.7%,HR 1.25,95%CI 0.93-1.69)
  • 死亡、心肌梗死或卒中复合终点及全因死亡率两组无显著差异
  • PCI组缺血驱动靶血管血运重建显著多于CABG组(16.1% vs 8.0%,HR 1.98,95%CI 1.21-3.21)

核心结论

  • 左主干病变PCI与CABG十年主要心脑血管不良事件发生率无显著差异。
  • 研究效能不足,结果应视为假说生成性,需进一步研究。

研究设计与样本

  • PRECOMBAT为随机对照试验,2004年4月至2009年8月在韩国13家医院纳入无保护左主干病变患者。
  • 患者随机接受西罗莫司洗脱支架PCI(n=300)或CABG(n=300),随访延长至至少10年,中位11.3年。

主要发现

  • 10年主要终点事件PCI组29.8%、CABG组24.7%(HR 1.25,95%CI 0.93-1.69)。
  • 死亡、心肌梗死或卒中复合终点18.2% vs 17.5%(HR 1.00,95%CI 0.70-1.44)。
  • 全因死亡率14.5% vs 13.8%(HR 1.13,95%CI 0.75-1.70)。
  • 缺血驱动靶血管血运重建16.1% vs 8.0%(HR 1.98,95%CI 1.21-3.21)。

临床怎么用

  • 左主干病变选择PCI或CABG时,十年硬终点(死亡、心肌梗死、卒中)未见显著差异。
  • PCI组靶血管血运重建风险更高,决策时需结合血运重建需求与患者因素综合考量。

局限性

  • 研究效能不足(underpowered),结果应视为假说生成性。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term comparative outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents and coronary-artery bypass grafting (CABG) for left main coronary artery disease are highly debated. METHODS: In the PRECOMBAT trial (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease), patients with unprotected left main coronary artery disease were randomly assigned to undergo PCI with sirolimus-eluting stents (n=300) or CABG (n=300) in 13 hospitals in Korea from April 2004 to August 2009. The follow-up was extended to at least 10 years for all patients (median, 11.3 years). The primary outcome was the incidence of major adverse cardiac or cerebrovascular events (composite of death from any cause, myocardial infarction, stroke, or ischemia-driven target-vessel revascularization). RESULTS: At 10 years, a primary outcome event occurred in 29.8% of the PCI group and in 24.7% of the CABG group (hazard ratio [HR] with PCI vs CABG, 1.25 [95% CI, 0.93-1.69]). The 10-year incidence of the composite of death, myocardial infarction, or stroke (18.2% vs 17.5%; HR 1.00 [95% CI, 0.70-1.44]) and all-cause mortality (14.5% vs 13.8%; HR 1.13 [95% CI, 0.75-1.70]) were not significantly different between the PCI and CABG groups. Ischemia-driven target-vessel revascularization was more frequent after PCI than after CABG (16.1% vs 8.0%; HR 1.98 [95% CI, 1.21-3.21). CONCLUSIONS: Ten-year follow-up of the PRECOMBAT trial of patients with left main coronary artery disease randomized to PCI or CABG did not demonstrate significant difference in the incidence of major adverse cardiac or cerebrovascular events. Because the study was underpowered, the results should be considered hypothesis-generating, highlighting the need for further research. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03871127 and NCT00422968.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Park DW, Ahn JM, Park H, et al. Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial. Circulation. 2020. PMID: 32223567. doi:10.1161/CIRCULATIONAHA.120.046039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。